Novartis AG v Pharmacor Pty Limited (No 2)

Link copied
Case Copied 19 min read

FEDERAL COURT OF AUSTRALIA

Novartis AG v Pharmacor Pty Limited (No 2) [2023] FCA 963   

File number: NSD 506 of 2023
Judgment of: YATES J
Date of judgment: 16 August 2023
Catchwords: PRACTICE AND PROCEDURE – patents – interlocutory application for question to be heard separately pursuant to r 30.01(1) of the Federal Court Rules 2011 (Cth) – where proposed separate question concerns the relevant time at which a patent applicant’s knowledge of the best method is to be fixed for the purposes of s 40(2)(a) of the Patents Act 1990 (Cth) – overarching purpose of civil practice and procedure provisions – determination of the costs of an additional interlocutory application no longer pressed
Legislation:

Federal Court of Australia Act 1976 (Cth) s 37M

Patents Act 1990 (Cth) ss 40, 192

Federal Court Rules 2011 (Cth) rr 21.01, 30.01

Cases cited:

GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 2) Ltd v Generic Partners Pty Ltd [2018] FCAFC 71; 264 FCR 474

Les Laboratoires Servier v Apotex Pty Ltd [2016] FCAFC 27; 247 FCR 61

Novartis AG v Pharmacor Pty Ltd [2023] FCA 804

Pfizer Overseas Pharmaceuticals v Eli Lilly & Co [2005] FCAFC 224; 225 ALR 416

Division: General Division
Registry: New South Wales
National Practice Area: Intellectual Property
Sub-area: Patents and associated Statutes
Number of paragraphs: 66
Date of hearing: 11 August 2023
Counsel for the Applicants: Mr T Cordiner KC
Solicitor for the Applicants: Clayton Utz
Counsel for the Respondent: Mr J Cooke SC and Mr D Larish
Solicitor for the Respondent: Ashurst Australia

ORDERS

NSD 506 of 2023
BETWEEN:

NOVARTIS AG

First Applicant

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED

Second Applicant

AND:

PHARMACOR PTY LIMITED

Respondent

ORDER MADE BY:

YATES J

DATE OF ORDER:

16 AUGUST 2023

THE COURT ORDERS THAT:

1.The interlocutory application dated 11 July 2023 as amended by the amended interlocutory application dated 14 July 2023, filed by the applicants (the first interlocutory application), be dismissed.

2.The applicants pay the respondent’s costs of the first interlocutory application.

3.The interlocutory application dated 26 July 2023, filed by the respondent (the second interlocutory application), be dismissed.

4.There be no order for costs in respect of the second interlocutory application, with each party to bear its own costs.

Note:   Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


REASONS FOR JUDGMENT

YATES J:

INTRODUCTION

  1. There are two interlocutory applications before me.

  2. The first is an amended interlocutory application filed by the applicants in the principal proceeding, Novartis AG and Novartis Pharmaceuticals Australia Pty Limited (Novartis Australia) (I will refer to both as, simply, Novartis), seeking the separate determination, pursuant to r 30.01(1) of the Federal Court Rules 2011 (Cth) (the Rules), of whether certain paragraphs of the amended statement of cross-claim filed by the respondent, Pharmacor Pty Limited (Pharmacor), and Pharmacor’s application for a declaration of invalidity in respect of claim 1 of Patent No. 2003206738 (the patent), should be…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited (No 2) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2023] FCA 963
Decision Date

CaseChat Overview and Summary

The case of Novartis AG v Pharmacor Pty Limited (No 2) involved an interlocutory application filed by Pharmacor seeking to compel Novartis to answer a specific interrogatory, and an application by Novartis seeking to determine a separate question regarding the timing of a patent applicant's knowledge of the best method for the purposes of s 40(2)(a) of the Patents Act 1990 (Cth). The Federal Court of Australia was tasked with deciding these applications, which were related to a broader dispute over the validity of a patent held by Novartis. The court had to consider whether the proposed separate question should be heard independently and whether the costs of an additional interlocutory application should be awarded.

The court determined that the overarching purpose of the civil practice and procedure provisions was to facilitate the just resolution of disputes according to law as quickly, inexpensively, and as efficiently as possible. The court noted that the applications arose from a previous case management hearing where the possibility of additional interlocutory applications had been raised. The court observed that circumstances had changed since that hearing, with Pharmacor narrowing its discovery request and Novartis having already provided the ordered discovery without finding any relevant documents. The court concluded that, given these developments and the potential for further interlocutory proceedings, it was in the interests of justice to dismiss both applications without awarding costs.

In summary, the Federal Court dismissed both interlocutory applications, with the first application being dismissed on the costs of the respondent and the second application having no order for costs, each party bearing its own costs. This decision underscores the importance of considering the overarching purpose of civil procedure provisions when dealing with interlocutory matters, particularly in the context of patent disputes.

Orders

Orders of the court

1. The interlocutory application dated 11 July 2023 as amended by the amended interlocutory application dated 14 July 2023, filed by the applicants (the first interlocutory application), be dismissed.

2. The applicants pay the respondent’s costs of the first interlocutory application.

3. The interlocutory application dated 26 July 2023, filed by the respondent (the second interlocutory application), be dismissed.

4. There be no order for costs in respect of the second interlocutory application, with each party to bear its own costs.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

The second is an interlocutory application filed by Pharmacor seeking an order, pursuant to r 21.01 of the Rules, that Novartis be ordered to answer a particular interrogatory.BACKGROUND In the principal proceeding, Novartis alleges that Pharmacor threatens to infringe claim 1 of the patent in relation to its apprehended supply of a number of pharmaceutical products entered on the Australian Register of Therapeutic Goods. Pharmacor denies that it threatens to infringe claim 1 and, by its amended statement of cross-claim, alleges that claim 1 is invalid on a number of grounds. It also alleges that, on 5 December 2016, the Commissioner of Patents wrongly granted an extension of the term of the patent to 16 January 2028. Absent that extension, the term of the patent would have expired on 16 January 2023. Pharmacor seeks an order that the Register of Patents be rectified pursuant to s 192 of the Patents Act 1990 (Cth) (the Act) to remove reference to the term of the patent having been extended, and recording that the term of the patent expired on 16 January 2023. The two interlocutory applications are related in that they concern a particular ground on which Pharmacor challenges the validity of claim 1 of the patent—namely, that the complete specification lodged in support of the application for the patent (the complete specification) did not, and does not, disclose the best method known to Novartis AG, as the applicant for the patent, of performing the invention (the best method), contrary to s 40(2)(a) of the Act (in the form which applies in this proceeding). In this connection, paragraphs 6 to 10 of the statement of cross-claim plead that the patent (meaning, the complete specification) does not disclose the best method that was known to Novartis AG before 5 April 2007 (referred to as the Date of Grant) or, alternatively, 28 November 2006 or 28 July 2006 (referred to as the Dates of Amendment) or, alternatively, 16 January 2003 (referred to as the Date of Filing). Pharmacor’s case in this regard has two broad strands. The first strand is that, at each of the alleged times, Novartis AG had knowledge of a pharmaceutical composition containing a compound of non-covalently bound valsartan (or a valsartan salt) and a neutral endopeptidase (NEP) inhibitor (or an NEP inhibitor salt), including where the NEP inhibitor was sacubitril (or a sacubitril salt) or sacubitrilat (or a sacubitrilat salt). The second strand is that, at each of the alleged times, Novartis AG had knowledge of Example 8 given in the complete specification, but did not include that example in the complete specification before those dates. Example 8 was introduced by voluntary amendments allowed on 16 January 2020. Novartis admits that it knew the information in Example 8 before the Date of Filing. It is also convenient to note at this point that, on 14 July 2023, I made an order that Novartis AG and Novartis Australia give discovery in respect of the following category of documents:1. All Documents created during the period from 16 January 1998 to the Date of Filing recording or evidencing the description and/or evaluation of any pharmaceutical composition and/or method of preparing any pharmaceutical composition comprising: (a) valsartan (or a pharmaceutically acceptable salt thereof); and (b) an NEP inhibitor (or a pharmaceutically acceptable salt thereof); and(c) a pharmaceutically acceptable carrier, in which the NEP inhibitor is sacubitril or sacubitrilat, and in which the valsartan (or a pharmaceutically acceptable salt thereof) and the NEP inhibitor (or a pharmaceutically acceptable salt thereof) are associated by non-covalent bonds.

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

Fourthly, Pharmacor says that, if I were to accede to Novartis’s interlocutory application, and if the proposed question were to be determined adversely to it, it would seek leave to appeal. Although its application would be made on an expedited basis, it is possible that seeking leave to appeal could bring into train events that could jeopardise the present listing of the trial to commence on 8 April 2024, or at least disrupt the orderly conduct of that trial.Consideration Section 37M of the Federal Court of Australia Act 1976 (Cth) requires me to approach the determination of this interlocutory application having regard to the overarching purpose of the Court’s civil practice and procedure provisions, which is to facilitate the just resolution of disputes according to law as quickly, inexpensively, and as efficiently as possible, bearing in mind a number of considerations, including: (a) the just determination of all proceedings before the Court; (b) the efficient use of the judicial and administrative resources available for the purposes of the Court; (c) the efficient disposal of the Court’s overall caseload; (d) the disposal of all proceedings in a timely manner; and (e) the resolution of disputes at a cost that is proportionate to the importance and complexity of the matters in dispute. The genesis of the present application appears to be a comment I made at a case management hearing on 6 July 2023 in the context of the parties raising the prospect of a number of interlocutory applications being filed. These concerned a complaint by Novartis about the generality of Pharmacor’s pleading of the first strand of its best method challenge, and Pharmacor’s expressed intention to seek discovery referable to Novartis AG’s knowledge of the best method as at the Date of Filing, the Dates of Amendment, and the Date of Grant. At that time I raised for consideration whether the determination of the relevant time at which a patent applicant’s knowledge is to be fixed for the purposes of s 40(2)(a) of the Act (in its relevant form) might best be considered in the context of the determination of a separate question, rather than in the context of a dispute about pleadings or a dispute about discovery. I should also say that, at that time, Novartis was not prepared to identify, with reference to the complete specification, what it was proposing to contend was the best method known to Novartis AG at any date. Since that case management hearing, circumstances have changed considerably. First, although, at that time, Pharmacor was seeking discovery in respect of the first strand of its best method challenge with reference to two time periods— 16 January 1998 to the Date of Filing, and between the Date of Filing and the Date of Grant—Pharmacor subsequently confined its interlocutory application for discovery to the first of those periods: Novartis AG v Pharmacor Pty Ltd [2023] FCA 804. Secondly, Novartis AG and Novartis Australia have now given discovery with respect to the category ordered on 14 July 2023. As I have noted, no documents were discovered.